We’re also sharing exciting data from our IL-27 program, SRF388, which remains on track for a December 2019 IND filing. We believe the inhibition of IL-27 is a promising therapeutic approach for certain cancers. Watch live for #IL27Insights here: https://t.co/4lvLIGFEr2